260 2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3-11 2018 * -11 rhil-11 rhil-11 rhil-11 rhil-11-11 R730. 5 A 1009-0460 2018 03-0260 - 07 1 1. 1 Thrombocytopenia PLT < 100 10 9 /L ITP DIC < 50 10 9 /L TTP HIT < 20 10 9 /L SLE HIV-1 < 10 10 9 /L 1 / AA AL 2-3 CTCAE-4. 03 4 1 1 CTCAE-4. 03 Ⅰ Ⅱ Ⅲ Ⅳ < + 1mmJK + 1mm < 50 75 WK8ZQ LLN <000 25 ~ ~ 000 75 25 50 WK12 /mm 000 3 /mm 3 3 3 WKW PLT < 75. 50. LLN < 025. ~75. 050. 25. 010 9 10 /L 9 /L LLN lower limit of normal ITP 5 AA 6 2007 ASH 7 *
2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 261 1. 2 rhil-11-11 IL-11 rhil-11 IL-11 - IL- 11Rα 130 rhil-11 gp130 T 11-12 2014 AABB 8 rhil-11 CIT 16 PLT < 10 10 9 /L 2016 rhil- 11 ITP 17 2017 rhil-11 AA 6 rhil-11 IL-11Rα 21 15 rhil-11-11 rhil-11 1 18 19 rhil-11 20 21-23 ITP Th1 24-25 9-10 IL-11 rhil-11 13 1991 2010 IL-11 11 rhil-11 1997 FDA rhil-11 rhil-11 2 rhil-11 13 2003 2. 1 CIT 16 CIT CFDA rhil-11 Ⅲ Ⅳ 14 1 ONS CIT 2014 / rhil-11 CIT 15 CSCO PLT 10 2014 10 9 /L PLT 20
262 2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 10 9 /L 26 rhil-11 rhil-11 rhtpo rhtpo TPO 30 1 Romiplostim Ehmmbopag 2. 1. 1 CIT 16 6 rhil-11 rhtpo CFDA ~ 24 h rhil-11 CIT 50 μg /kg 1 7 ~ 14 100 10 9 /L rhil-11 rhtpo 50 10 9 /L 27-28 rhil-11 2 rhil-11 29 rhtpo 1 1 CIT 2. 1. 2 CIT secondary prevention 1 16 Ⅲ /Ⅳ ICH AL 31 CIT 1 2 PLT < 75 10 9 /L 3 AL 4 5 ECOG 2 6 Ⅲ /Ⅳ IL-11 AML 6 ~ 24 h 32 PLT < 75 10 9 /L 2. 2. 1 PLT 100 10 9 /L rhil-11 50 μg /kg 2. 2. 2 1 2 primary prevention rhil-11 AL 2 1 2. 2
2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 263 1 2 rhil-11 6 ~ 24 h rhil- 11 50 μg /kg 1 7 ~ 14 1 rhil- 2 3 11 4 ECOG 2 5 AL 2. 3 IL-11 IL-3 SCF PLT 100 10 9 /L 19 AL 24 35 h rhil-11 33-34 rhil-11 36 rhil-11 rhil-11 37 rhil-11 2 33 rhil-11 2. 2. 3 rhil-11 rhil-11 rhil-11 AML Ⅱ /Ⅲ rhil-11 2017 rhil-11 AA 2. 8% vs. 21. 6% P = 6 rhil-11 50 μg /kg 0. 0012 15 1 12 PLT 100 10 9 /L OS DFS 2. 4 ITP rhil-11 ITP 21 20 18 IL-11 adipogenesis inhibitory factor AGIF rhil-11 rhil-11 AA 5 rhil-11 2016 rhil-11 ITP PLT < 10 10 9 /L ITP
264 2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 2016 rhil-11 ITP 17 1 ~ 2 3. 2. 3 rhil-11 rhil-11 ITP γ- 38-39 14 rhil-11 50 μg /kg 43 1 14 PLT 200 10 9 /L 24 rhil-11 ITP CD4 + T Th1 rhil-11 Th2 T-bet mrna GATA-3 mrna 3 2 kg IL-11 ITP 25 ITP Th1 Th2 Th Th1 T-bet rhil-11 GATA-3 rhil-11 Th1 Clcr < 30 ml /min T-bet GATA-3 25 μg /kg 1 3. 3. 2 rhil-11 44 3 3 rhil-11 9-10 21 3. 1 rhil-11 rhil-11 10 41-42 rhil-11 3. 2 3. 2. 1 ESC rhil-11 45 3. 45% 1 ~ 2 3 ~ 4 14 rhil-11 45-46 42 3. 2. 4 rhil-11 5% rhil-11 3. 3 3. 3. 1 rhil-11 8% rhil-11 14 rhil-11 rhil-11 - - RAAS 43 rhil-11 3. 2. 2 rhil-11 25 μg /kg 7. 7% 33 7 ~ 14 h 39
2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 265 CHF rhil-11 1 47 2016 37 2 89-93. rhil-11 1 ~ 2 178. 48-50 1 4 10 Isaacs C Robert NJ Bailey FA et al. Randomized placebocontrolled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubi- rhil-11 rhil-11 rhil-11 cin J rhil-11 poietic rhil-11 14 Suppl 1 53-61. 2018-01-12 1. 11 2016 5. J. 2010 32 12 18. -11 J. 948-950. 2006 19 2 125-128. 2 Michelson AD. The clinical approach to disorders of platelet number and function M / /Michelson AD. Platelets 3rd ed. Pittsburgh Academic Press 2013 813-818. 3. J. 20 Ellis M Zwaan F Hedstr m U et al. Recombinant human interleukin 2013 33 22 1874-1877. 4 National Cancer Institute. Common terminology criteria for adverse 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy a double-blind pla- events CTCAE Version 4. 0. 3 EB /OL. 2010-06-14 cebo-controlled randomised trial J. Lancet 2003 361 2018-01-12. https / /ctep. cancer. gov /protocoldevelopment / adverse_effects. htm. 5. 2016 J. 6. 2017 J. 2017 38 1 1-5. 7 Slichter SJ. Evidence-based platelet transfusion guidelines J. Hematology Am Soc Hematol Educ Program 2007 1 1 172-8 Kaufman RM Djulbegovic B Gernsheimer T et al. Platelet transfusion A clinical practice guideline from the AABB J. Ann Intern Med 2015 162 3 205-213. 9 Tepler I Elias L Hussein M et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy J. Blood 1996 87 9 3607-3614.. J Clin Oncol 1997 15 11 3368-3377. 11 Schwertschlag US Trepicchio WL Dykstra KH et al. Hemato- immunomodulatory and epithelial effects of interleukin-11 J. Leukemia 1999 13 9 1307-1315. 12 Turner KJ Neben S Weich N et al. The role of recombinant interleukin 11 in megakaryocytopoiesis J. Stem Cells 1996 13 Pfizer Inc. NEUMEGA Instrument EB /OL. 2012-10-30. https / /www. pfizer. com /products /product-detail / neumega. 14. 11 EB / OL. 2007-04-22 2018-01-12. http / /www. qilu-pharma. com /products detail /product Id 51. html. 15 Polovich M Whitford JM Olsen M et al. Chemotherapy and biotherapy guidelines and recommendations for practice M. 4th ed. Oncology Nursing Society 2014. 16. 2014 J. 2014 36 11 876-879. 17. M. 19 Keller DC Du XX Srour EF et al. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures J. Blood 1993 82 5 1428-1435. 9354 275-280. 21 Usuki K Urabe A Ikeda Y et al. A multicenter randomized
266 2018 3 23 3 Chinese Clinical Oncology Mar. 2018 Vol. 23 No. 3 double-blind placebo-controlled late-phase Ⅱ /Ⅲ study of recombinant human interleukin 11 in acute myelogenous leukemia J. Int J Hematol 2007 85 1 59-69. 22. -11 38. -11 J. 2011 51 25 11 J. - 11. 2006 14 4 417-418. 23. -11 39. 11 J. 26 J. 2010 37 9 710-712. 2008 16 5 1219-1221. 24. IL-11 ITP Th1 Th2 T-bet GATA-3 mrna J 2014 44 7 494-497. 25 Lin Y Zhou X Guo W et al. RhIL-11 treatment normalized Th1 /Th2 and T-bet /GATA-3 imbalance in in human immune thrombocytopenic purpura ITP J. Int Immunopharmacol 2016 38 40-44. 26 Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy J. Oncology 2015 29 4 282-294. 27. rhtpo rhil-11. biology and clinical use J. Blood 1997 89 11 3897-3908. AML J. nemia in healthy subjects J. J Clin Pharmacol 2000 40 8 2015 13 10 1564-1566. 880-888. J. 2010 25 3 318-320. 29. -11 J. 2008 24 10 1805-1806. 45 Zamorano JL Lancellotti P Rodriguez MD et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity de- 30. -11 veloped under the auspices of the ESC Committee for Practice J. Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology ESC J 2008 15 14 1119-1120.. 31. Eur J Heart Fail 2017 19 1 9-42. J. 2004 7 5 7 46. -11-8. J. 2014 17 7 32 Tafuri A Lemoli RM Petrucci MT et al. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells J. Exp Hematol 1999 27 8 1255-1263. 33. 11 myocytes as the target of interleukin 11 a cardioprotective cytokine J. Cytokine 2007 38 2 107 - J. 115. 2006 27 3 190-192. 34. -11 signal transducer and activator of transcription 3 by interleukin-11 130 J. ameliorates cardiac fibrosis after myocardial infarction J. Circulation 2010 121 5 684-2007 27 17 1376-1378. 691. 36. 11 J. 2010 31 10 710-711. 37. -11 J. 2005 11 3 128-131. 40 Du X Williams DA. Interleukin-11 review of molecular cell 41. 11 J. 2001 9 4 314-317. 42. J. 2015 20 9 841-847. 43 Dykstra KH Rogge H Stone A et al. Mechanism and amelioration of recombinant human interleukin-11 rhil-11 -induced a- 28. 44 Sartiani L De PP Lonardo G et al. Does recombinant human -11 interleukin-11 exert direct electrophysiologic effects on single human atrial myocytes J. J Cardiovasc Pharmacol 2002 39 3 425-434. 849-852. 47 Nd SJ. Tolerability and side-effect profile of rhil-11 J. Oncology 2000 14 8 41-47. 48 Kimura R Maeda M Arita A et al. Identification of cardiac 49 Obana M Maeda M Takeda K et al. Therapeutic activation of 35. 11 50 Nakagawa M Owada Y Izumi Y et al. Four cases of investigational therapy with interleukin-11 against acute myocardial J. 2002 8 4 230-232. infarction J. Heart & Vessels 2016 31 9 1-5. 2018-01 - 20